Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy

Published:2015-08-11 Issue:11 Volume:19 Page:1143-1156
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Li Zhanguo¹,Zhang Fengchun²,Kay Jonathan³,Fei Kaiyin⁴,Han Chenglong⁵,Zhuang Yanli⁶,Wu Zhong⁷,Hsia Elizabeth C.⁴⁸

Affiliation:

1. Department of Rheumatology and Immunology; Peking University People's Hospital; Beijing China

2. Rheumatology and Clinical Immunology; Peking Union Medical College Hospital; Beijing China

3. Division of Rheumatology; Department of Medicine; University of Massachusetts Medical School and UMass Memorial Medical Center; Worcester Massachusetts USA

4. Immunology; Janssen Research & Development, LLC; Spring House Pennsylvania USA

5. Patient-Reported Outcomes; Janssen Global Services; Malvern Pennsylvania USA

6. Biologics Clinical Pharmacology; Janssen Research & Development, LLC; Spring House Pennsylvania USA

7. Clinical Biostatistics; Janssen Research & Development, LLC; Spring House Pennsylvania USA

8. Perelman School of Medicine at the University of Pennsylvania; Philadelphia Pennsylvania USA

Funder

AbbVie

Epirus Biopharmaceuticals, Inc.

Genentech Inc.

Hospira, Inc.

Janssen Biotech

PanGenetics, B.V.

Pfizer

Samsung Bioepis

UCB, Inc.

Janssen Research and Development

Ardea Biosciences, Inc.

Eli Lilly and Company

Roche Laboratories, Inc.

Alexion Pharmaceuticals

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb Co.

Crescendo BioScience Inc.

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.12723/fullpdf

Reference36 articles.

1. Rheumatoid arthritis;Klareskog;Lancet,2009

2. The pathogenesis of rheumatoid arthritis;McInnes;N Engl J Med,2011

3. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy;Emery;Arthritis Rheum,2011

4. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis;Emery;Arthritis Rheum,2009

5. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study;Keystone;Ann Rheum Dis,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study;The Lancet Regional Health - Western Pacific;2024-01

2. Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases;RMD Open;2023-12

3. Safety and Efficacy of Golimumab in Rheumatoid Arthritis: A Prospective, Multicenter, Real-World Study from India;Indian Journal of Rheumatology;2023-07-14

4. Comparative Efficacy of bDMARDs and tsDMARDs for the Treatment of Rheumatoid arthritis: A Systematic Review and Network Meta-Analysis;International Journal of Biology and Life Sciences;2023-06-01

5. The Risk of Adverse Effects of TNF-α Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis;Frontiers in Immunology;2022-02-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3